Myofibrillar myopathies (MFMs) are a heterogeneous group of skeletal and cardiac muscle diseases. In this review, we highlight recent discoveries of new genes and disease mechanisms involved in this group of disorders.
INTRODUCTION
Myofibrillar myopathies (MFMs) are a genetically heterogeneous group of skeletal and cardiac muscle disorders characterized by focal dissolution of myofibrils and aggregation of degraded myofibrillar products into inclusions containing desmin and a number of other proteins [1] . A major morphological feature unifying these genetically diverse disorders is that myofibrillar degeneration starts at or close to the Z-disc of the sarcomere [1, 2] . Regarding its major pathogenic mechanisms, MFM is also part of a group recently designated as protein aggregate myopathies (PAM) [3, 4] . The use of new technologies, including next-generation sequencing, laser microdissection and mass spectrometrybased proteomics followed by gene sequencing, has recently helped to identify disease causative genes in a fraction of patients and will hopefully enlarge the spectrum of MFM causative genes in the very near future. This should increase the reliability of diagnostic procedures and aid develoment of therapeutic options for each MFM subtype. A number of detailed reviews focusing on MFMs have been published over the past 2-5 years [2, [5] [6] [7] . This review summarizes the latest relevant advances in the field.
NOVEL MYOFIBRILLAR MYOPATHY SUBTYPES
Most recently, genetic causes of two disorders have been identified: reducing body myopathy (RBM) and hereditary myopathy with early respiratory failure (HMERF), both considered to be new members of MFM.
Reducing body myopathy RBM, originally described by Brooke and Neville [8] , is a rare congenital disorder defined by the presence of intracytoplasmic inclusions that reduce nitroblue tetrazolium (NBT) and thus stain strongly with menadione-NBT. In 2008, a very elegant work using laser microdissection followed by proteomic analysis resulted in the identification of FHL1 as the most abundant protein within the reducing bodies [9] . Subsequently, mutations in FHL1 on chromosome Xq27.2 were discovered in affected children [9] . RBM manifests with a range of phenotypes extending from early onset fatal conditions to milder disorders manifesting in childhood or adulthood [9] [10] [11] [12] [13] . Besides RBM, mutations in FHL1 have been identified in patients with several other X-linked disorders including X-linked myopathy with postural muscle atrophy and muscle hypertrophy [14] , scapuloperoneal myopathy [15] , rigid spine syndrome [16] , Emery-Dreifuss muscular dystrophy [17] , hypertrophic cardiomyopathy [18] and some other overlapping conditions. Reducing bodies have been detected in severe childhoodonset and juvenile-onset cases of RBM caused by mutations in the second LIM domain of FHL1 [12, 13] , but lately they were also identified in lateonset cases with mutations in the C-terminal domain [19 & ]. Besides FHL1, which constitutes the most abundant protein found in reducing bodies, immunohistochemical analyses have led to the identification of several other proteins within or surrounding the reducing bodies, including desmin and myotilin [9] [10] [11] [12] 19 & ,20-22], allowing classification of this entity as a PAM. Moreover, early Z-line abnormalities, Z-line streaming and reducing body material arising from the level of the Z-line and spreading under the sarcolemma and within the myofibrils to form reducing bodies [10,11,19 & ,20, 21] , as revealed by electron microscopy (EM) analysis, are other features that make the relationship to MFM certain, although the histochemical, immunohistochemical and ultrastructural characteristics are profoundly different from the other MFM subtypes.
Hereditary myopathy with early respiratory failure HMERF is an autosomal dominant disease characterized by proximal and distal muscle weakness associated with respiratory insufficiency and involvement of neck flexors early in the disease course [23] . A p.R32450W mutation in the kinase domain of titin was identified in Swedish families, originally described by Edström [24] ]. These histopathological and ultrastructural features justify that HMERF associated with mutation in the A-band of titin is classified as MFM-titinopathy. However, the presence of cytoplasmic bodies as the morphological hallmark in HMERF distinguishies HMERF from other MFM subtypes.
Proteomic analysis in MFM
Proteomic analysis has become a valuable method in MFM research. It enables highly sensitive detection
KEY POINTS
Mutations in eight genes are now known to cause MFMs, skeletal and cardiac muscle disorders characterized by focal dissolution of myofibrils and aggregation of degraded myofibrillar products into proteinacious aggregates.
The discovery of the latest two genes, FHL1 and TTN, the identification of new mutations in the previously identified MFM genes and the elucidation of disease mechanisms were achieved by the use of novel technologies: next-generation sequencing, laser microdissection and mass spectrometry-based proteomics.
Molecular studies of large groups of patients with MFMs helped to outline new MFM phenotypes such as arrhythmogenic right ventricular cardiomyopathy and find a classification niche for other diseases having features of MFMs.
Progress in molecular studies of MFMs in combination with classical morphological and ultrastructural approaches leads to improvements in diagnostics and opens up the prospects for the development of subtypespecific prevention and therapy. and quantitation of proteins even in very small samples [19 & 
Laser microdissection selectively collects aggregates from abnormal muscle fibers and control samples from normal appearing fibers of the same biopsy ( Fig. 3 ). Mass spectrometry-based quantitative proteomic analysis of these paired samples allows identification of proteins that are overrepresented in aggregates. This approach has provided new insights into the composition of pathological protein aggregates in several MFM subtypes [19 & ,31 & -33 & ], and has revealed significant differences between the MFM subtypes regarding the accumulation ratio and the abundance of proteins in aggregates ( Fig. 3) , to the extent that the subtype-specific proteomic profiles can be successfully used for differential
The finding that the disease-causing proteins show stronger accumulation in filaminopathy, desminopathy and RBM [19
suggests that proteins overrepresented in aggregates of patients with so far unsolved MFM-related conditions are the potential disease-causing candidates. Nextgeneration sequencing can in this situation be used to search for mutations in genes encoding these proteins.
PROGRESS IN STUDIES OF THE PREVIOUSLY IDENTIFIED MYOFIBRILLAR MYOPATHIES
Mutations in sarcomeric and Z-disc-supporting cytoskeletal proteins, desmin (DES), aB-crystallin (CRYAB), myotilin (MYOT), Z band alternatively spliced PDZ-containing protein (ZASP), filamin C (FLNC) and Bcl-2-associated athanogene-3 (BAG3) have previously been identified in patients with MFM (Table 1) .
Desminopathy
MFM resulting from mutations in desmin (DES) is the most common and best studied subtype of MFM [34-36,37 && ]. Thus far, 67 disease-causing DES mutations have been reported [37 && ]. Clinical manifestations of desminopathy are heterogeneous. Skeletal myopathy is often associated with cardiac involvement: this has recently been the subject of extended studies [38,39 & ] stressing the need for close cardiac monitoring in desminopathy patients. Desmin mutations have recently been found in a subset of patients suffering from arrhythmogenic right ventricular cardiomyopathy [40] . Also, exome sequencing identified a DES mutation in affected members of a Swedish family with MFM and arrhythmogenic right ventricular cardiomyopathy [41 & ], previously reported by Melberg et al. [42] . The first recessive desmin-null mutation was reported in two siblings manifesting with a progressive myopathy, muscle fatigue, swallowing difficulties and respiratory restriction. Affected muscles showed myopathic abnormalities and cytochrome c ]. The disease in this family was previously mistakenly linked to a 6q23 locus and designated as limb-girdle muscular dystrophy (LGMD) 1D/1E. Transfection experiments, animal models and in-vitro assembly studies have been carried out to investigate the pathogenesis of desminopathy (reviewed in [37 && ]). Abnormal desmin filament elasticity has been postulated as a contributory mechanism of disease progression. A recent study performed in primary cultured myoblasts obtained from a patient revealed abnormal mechanical properties of affected muscle cells, which acquire increased stiffness and higher vulnerability to mechanical stretch [45 & ]. A useful disease model has been generated by inoculating adeno-associated virus vectors carrying mutant desmin cDNA into the anterior tibialis muscle of a mouse. The results demonstrate mutation-dependent effects on muscle regeneration, distribution of fiber size and generation of muscle force [46 & ]. This technology may help to assess the level of pathogenicity of various desmin mutations.
aB-crystallinopathy
aB-crystallinopathy represents an infrequent subtype of MFM. A heterozygous CRYAB p.R120G mutation was identified in a large French family presenting with proximal upper limb and distal lower limb weakness, involvement of the velopharyngeal muscles, respiratory failure, cardiopathy and lens opacities. Granulofilamentous material, the characteristic ultrastructural feature of desmin deposits, has for the first time been described in this family [47, 48] . Analysis of a second kindred manifesting identical symptoms [49 & ] caused by a novel D109H CRYAB mutation confirmed that aB-crystallinopathy is a multisystem disorder. A few further cases have been reported presenting in adulthood with muscle weakness and respiratory failure, or weakness and peripheral neuropathy but no cardiac involvement or lens opacities [50, 51] . LGMD, limb-girdle muscular dystrophy; MFM, myofibrillar myopathy. A knock-in mouse model for the CRYAB p.R120G mutation has been developed [52] ; analysis of the affected tissues show the loss of aB-crystallin solubility and accumulation of protein aggregates in the lens and skeletal muscle, thus recapitulating many features of the human disease.
Recessive mutations in CRYAB have been identified as the cause of fatal infantile hypertonic muscular dystrophy described two decades ago in Canadian natives [53, 54] . Affected children presented shortly after birth with severe weakness and hypertonia, predominantly in axial muscles, and progressive respiratory insufficiency leading to early death. Muscle biopsies showed typical features of MFM, although aB-crystallin was not detected in the inclusions by using monoclonal antibody that recognizes the entire protein [53, 54] .
Myotilinopathy
MFM resulting from MYOT mutations is a late-onset disorder presenting with distal weakness of lower limbs or limb-girdle weakness followed by distal muscle involvement [55] [56] [57] . Peripheral neuropathy, respiratory failure and cardiomyopathy are rare associated findings [56, 57] . To date, 50 MFM patients from 40 unrelated families with MYOT mutations have been identified. All mutations except for one are located in exon 2 of the MYOT gene [56] [57] [58] .
Recent studies in transfected COS7 cells and myotubes have demonstrated reduced myotilin degradation by the proteasome system and accumulation of mutant myotilin in the transfected cells, which perfectly explains the disease mechanisms in human myotilinopathy [59] . New observations support previous results from studies of human MFM muscle biopsies that suggested a major role for impaired protein degradation in the pathogenesis of MFM [60,61 & ]. The pathogenic effects of MYOT mutations in vivo were also studied by using electroporation to express mutant myotilin in mouse skeletal muscles; abnormal insoluble protein aggregates were similar to those observed in patients with myotilinopathy [62 & ].
ZASPopathy
The clinical and pathological phenotype in patients carrying ZASP mutations is similar to the one described in myotilinopathy. First clinical symptoms usually occur in the sixth decade, the disease progression is very slow and patients remain ambulatory until very late age. Peripheral neuropathy and cardiac involvement are associated features in a minority of cases [63, 64] .
Recently, the p.D117N ZASP variant previously found to be associated with dilated cardiomyopathy was reported in a mother and child with symptoms of skeletal myopathy [65] . Three muscle biopsies performed in the mother showed neurogenic features but no MFM pathology, making it uncertain if the p.D117N ZASP variant was the cause of myopathy in this family.
A new p.V566 M ZASP mutation was identified in a single case of sporadic inclusion body myositis (sIBM) diagnosed according to the existing diagnostic criteria [66] . This is not surprising because some of the pathological features of sIBM overlap with those encountered in MFM, although large protein aggregates and major sarcomere disorganization are not usually seen in sIBM.
MFM-filaminopathy
MFM-filaminopathy is characterized by adult-onset predominantly proximal weakness with involvement of respiratory muscles and cardiac abnormalities [61 & ,67,68 & ]. The p.W2710X mutation located in the dimerization domain of filamin C was recently identified as a mutational hotspot [61 & ]. Late-onset cerebellar ataxia has been reported in one sporadic patient with FLNC p.T241 M mutation, but a causal relationship with filaminopathy is unclear [69] . Established cell culture models show significant protein aggregation and are applicable for testing therapeutic approaches [61 & ]. Two reported fish models [70, 71] relate rather to distal myopathy caused by haploinsufficiency than MFM-filaminopathy.
BAG3-myopathy
Mutations in BAG3 cause a rare subtype of MFM; only 12 patients, all carrying the same p.P209L recurrent de-novo mutation transmitted from a mosaic parent, have been reported to date [72] [73] [74] [75] . Unlike other subtypes of MFM, BAG3myopathy manifests during the first decade of life with rapidly progressive limb and axial muscle weakness, contractures, hypertrophic cardiomyopathy and respiratory insufficiency. A characteristic feature of the disease is the association with peripheral neuropathy that may in some patients be the initial clinical manifestation [75] . Nerve biopsies reveal a loss of myelinated fibers and the presence of giant axons with thin myelin sheets as characteristic features [73, 75] . Muscle biopsies are consistent with MFM, sometimes associated with signs of chronic denervation.
DIAGNOSIS
The diagnosis of MFM is based on muscle biopsy findings that demonstrate characteristic aggregates containing desmin and other proteins as revealed by immunohistochemistry [1, 2] (Fig. 1) . By EM, the initial abnormalities are often localized at or close to the Z-lines (Fig. 2) . This is followed by disruption of sarcomeres that become replaced by degraded material which accumulates in various patterns [2, 5, 76, 77] . In spite of myopathological similarities, individual MFM subtypes have distinct clinical morphological and muscle imaging features [76] [77] [78] . A summary of MFM gene-dependent phenotypic features is provided in Table 1 . Genetic testing is essential for establishing an accurate diagnosis of MFM, providing appropriate genetic counseling, and timely prevention of cardiac arrhythmia and heart failure.
CONCLUSION
The latest discoveries in the field of MFM have led to the identification of new genes and disease mechanisms involved in the causation of this group of disorders. Further molecular studies of MFMs in combination with classical myopathological approaches will potentially result in improvements in diagnosis and the development of subtype-specific prevention and therapy. This is a proteomic analysis in MFM-filaminopathy disclosing novel binding partners of filamin C. The authors identify a highly similar proteomic profile of aggregates in patients with different FLNC mutations and discuss the prospects of mass spectrometric analysis in MFM. 33.
